Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II trial of injectable LX22001 versus esomeprazole after endoscopic hemostasis for peptic ulcer bleeding
ChiCTR2500099377Phase 2Completed
- Sponsor
- Ruijin Hospital
- Start
- Jan 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of LX22001 and esomeprazole in Peptic ulcer disease (PUD) and upper gastrointestinal bleeding (UGIB) (3 arms), sponsored by Ruijin Hospital. Primary endpoint: Rebleeding-free rate within 72 hours after drug initiation. Started Jan 2025; status: completed.
02
Drugs
LX22001esomeprazole
03
Conditions
Peptic ulcer disease (PUD)upper gastrointestinal bleeding (UGIB)
Beyond the preview
Go deeper on ChiCTR2500099377.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500099377.